Comparison of the Effect of Vaseline and Bepanthen® "Wund- Und Heilsalbe" on the Wound Healing Following Laser Therapy (CO2)

May 29, 2018 updated by: RWTH Aachen University

Comparison of the Effect of Vaseline and Bepanthen® "Wund- Und Heilsalbe" on the Wound Healing Following Fractional Ablative Laser Treatment of Photo-damaged Skin

In the field of dermatology the healing process and therefore the success of a laser treatment are strongly determined by an appropriate postoperative treatment of the laser-treated skin. The manufacturer of CO2 laser systems recommends the application of Vaseline postoperatively to protect the treated tissue from air exposition until encrustation of the laser-treated skin decreases (usually after 7-14 days). An alternative to Vaseline could be Bepanthen® "Wund- und Heilsalbe" (Bayer). It contains the active ingredient pro-vitamin Dexapanthenol, which is widely used in dermatology therapy. The product helps to stabilize the protective barrier of the skin, to reduce the skin irritation, to stimulate the skin regeneration and to promote the wound healing. In an in-vitro study Bepanthen® "Wund- und Heilsalbe" triggered wound closure significantly faster compared to Vaseline. In this study the effect of Bepanthen® "Wund- und Heilsalbe" on wound healing should be investigated and compared to Vaseline in vivo following fractional ablative CO2 laser treatment of photo-damaged skin.

Study Overview

Status

Completed

Conditions

Detailed Description

The healing process and therefore the success of a laser treatment are strongly determined by an appropriate treatment with special skin care products of the laser-treated skin. Cooling measures prevent the swelling of the treated skin area, if applied directly after the procedure. A soothing and wound-healing-promoting care applied subsequently for seven days, can support and also speed up the healing process.

The Lumenis® Company is the manufacturer of CO2 laser systems and recommends the application of the Okklusiv ointment Vaseline® postoperatively, in order to prevent the treated tissue to the air exposition. These occlusive wound care should be maintained, until the encrustation of the laser-treated skin decreases, which usually happens 7-14 days postoperatively.

The Bepanthen® Wund- und Heilsalbe (Bayer) could be a possible alternative to Vaseline® as postoperative care. Bepanthen® Wund- und Heilsalbe contains pro-vitamin Dexpanthenol as an active ingredient and is widely used in dermatological therapy. The product helps to stabilize the protective barrier of the skin, to reduce the skin irritation, to stimulate the skin regeneration and to promote the wound healing. The investigators examined the effect of substances containing Dexpanthenol on wound healing process applied topically, in three-dimensional (3D) dermal skin equivalents in vitro. For this purpose, many lesions with standardized diameter and depth were generated using a laser. The subsequent topical application of substances containing dexpanthenol on the wound healing models (treated with laser) for three-days led to a significantly faster wound closure compared to Vaseline-covered models (Marquardt et al., 2015). The aim of this study is to compare the effect of white Vaseline with Bepanthen® "Wund- und Heilsalbe" (both applied postoperatively) on the wound healing following fractional ablative CO2 laser treatment of photo-damaged skin in vivo.

Study Type

Interventional

Enrollment (Actual)

37

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • NRW
      • Aachen, NRW, Germany, 52057
        • University Hospital RWTH Aachen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥ 18 years
  • photodamaged skin, which need to be treated with the fractional ablative CO2 laser

Exclusion Criteria:

  • pregnant or lactating females
  • chronic diseases such as diabetes and vascular disease with impaired wound healing
  • Patients, who tend to form hypertrophic scars and keloids
  • Patients, who take the isotretinoin-containing medication in the past year
  • topical or systemic corticosteroid treatment
  • immunocompromised patients
  • Patients with the Koebner phenomenon
  • People with the skin type 6
  • Patients with melanoma

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Bepanthen/Vaseline
One half of the wound occuring after CO2 laser therapy of photo-damaged skin is treated with Bepanthen and the other half with Vaseline.
Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked "V". Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home.
After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked "B". Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of the diameter of the individual lesions [initial value 1.3mm] between study visits.
Time Frame: Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
Large clinical digital photos as well as dermatoscopic images of the skin.
Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
Change of the size of the individual lesions between study visits.
Time Frame: Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
Two-dimensional microscopic skin cut images in real time of the skin.
Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
Visual changes of the wound healing between study visits.
Time Frame: Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
The wound healing rates will be visually assessed, based on the measure of re-epithelialization.
Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
Change of the wound under cosmetic aspects between study visits.
Time Frame: Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
The cosmetic result is based on a visual analog scale (VAS) from 0 (bad) to 10 (excellent, with no visible difference of the wound to the surrounding tissue).
Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of the transepidermal water loss (TEWL) between study visits.
Time Frame: Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
TEWL is the most important parameter for the assessment of skin barrier function.
Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jens M. Baron, Prof. Dr. med., RWTH Aachen University, Department of Dermatology and Allergology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2017

Primary Completion (Actual)

January 22, 2018

Study Completion (Actual)

February 5, 2018

Study Registration Dates

First Submitted

February 24, 2017

First Submitted That Met QC Criteria

March 23, 2017

First Posted (Actual)

March 30, 2017

Study Record Updates

Last Update Posted (Actual)

May 30, 2018

Last Update Submitted That Met QC Criteria

May 29, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 16-011

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Photodamaged Skin

Clinical Trials on CO2-laser

3
Subscribe